全文获取类型
收费全文 | 76795篇 |
免费 | 41749篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 1488篇 |
儿科学 | 4309篇 |
妇产科学 | 523篇 |
基础医学 | 15256篇 |
口腔科学 | 5052篇 |
临床医学 | 12920篇 |
内科学 | 23309篇 |
皮肤病学 | 7463篇 |
神经病学 | 13228篇 |
特种医学 | 2151篇 |
外科学 | 13715篇 |
综合类 | 15篇 |
一般理论 | 21篇 |
预防医学 | 4338篇 |
眼科学 | 1215篇 |
药学 | 5492篇 |
中国医学 | 1006篇 |
肿瘤学 | 7067篇 |
出版年
2024年 | 26篇 |
2023年 | 164篇 |
2022年 | 111篇 |
2021年 | 1322篇 |
2020年 | 5215篇 |
2019年 | 10831篇 |
2018年 | 10172篇 |
2017年 | 11536篇 |
2016年 | 12162篇 |
2015年 | 12022篇 |
2014年 | 11925篇 |
2013年 | 12394篇 |
2012年 | 3975篇 |
2011年 | 3903篇 |
2010年 | 8931篇 |
2009年 | 5387篇 |
2008年 | 1963篇 |
2007年 | 772篇 |
2006年 | 862篇 |
2005年 | 642篇 |
2004年 | 628篇 |
2003年 | 643篇 |
2002年 | 731篇 |
2001年 | 773篇 |
2000年 | 712篇 |
1999年 | 284篇 |
1998年 | 56篇 |
1997年 | 47篇 |
1996年 | 46篇 |
1995年 | 44篇 |
1994年 | 34篇 |
1993年 | 27篇 |
1992年 | 27篇 |
1991年 | 21篇 |
1990年 | 19篇 |
1989年 | 14篇 |
1988年 | 17篇 |
1987年 | 18篇 |
1986年 | 15篇 |
1985年 | 13篇 |
1984年 | 8篇 |
1983年 | 15篇 |
1982年 | 8篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1979年 | 8篇 |
1974年 | 3篇 |
1972年 | 3篇 |
1969年 | 6篇 |
1967年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
92.
93.
M. C. Robson MD a ; L. G. Phillip MD ; D. M. Cooper RN PhD a ; W. G. Lyle MD ; L. E. Robson RN MS ; L. Odom RN ; D. P. Hill PharmD ; A. F. Hanham MD ; G. A. Ksander MS 《Wound repair and regeneration》1995,3(2):157-167
Transforming growth factor-beta(2) promotes healing in a variety of animal models and exhibits clinical effects thought to be mediated by connective tissue formation. Two clinical trials were conducted to evaluate the safety and effect of transforming growth factor-beta(2) purified from bovine bone and delivered topically to venous stasis ulcers three times per week for up to 6 weeks by means of a lyophilized collagen vehicle. The first was an open-label trial comparing transforming growth factor-beta(2) purified from bovine bone (0.5 microg/cm(2)) with a placebo consisting of lyophilized collagen vehicle-without active drug. After no safety issues arose in that trial, a prospectively randomized, closed-label, observer-blinded, three-armed trial was conducted to compare bovine transforming growth factor-beta(2) (2.5 microg/cm(2)) with the collagen matrix placebo vehicle and with a standard dressing. Standardized elastic compression was applied to all test extremities. The rate of reduction of ulcer area as measured by planimetry was the primary measure of effect. No serious safety-related events occurred in either trial. Clinical evaluation suggested that improvement in the quality and quantity of granulation tissue appeared to precede epithelialization of ulcers treated with bovine transforming growth factor-beta(2). In both studies, treatment with bovine transforming growth factor-beta(2) appeared to have a positive effect on the rate of ulcer closure, whereas ulcers in the control groups continued to exhibit impaired healing. In the open-label study, the mean rate of closure of ulcers treated with bovine transforming growth factor-beta(2) was significantly greater than that of ulcers treated with placebo. There was likewise enhanced reduction in ulcer area in the ulcers treated with bovine transforming growth factor-beta(2) in the second trial. However, because of a higher variability in patient response and a greater placebo effect, the difference was not significant. The placebo was not worse than the standard care arm, thereby showing that the vehicle is not injurious to healing. The combined results of the two trials suggest that, at doses of 0.5 to 2.5 microg/cm(2), bovine transforming growth factor-beta(2) is safe as a topically applied agent in a collagen matrix vehicle and can have a positive effect on closure of venous stasis ulcers. Large multicenter trials appear to be indicated to evaluate fully the potential utility of transforming growth factor-beta(2) in accelerating closure of chronic dermal ulcers. 相似文献
94.
C Joseph Muniz Arthur C Fleischer Edwin F Donnelly Murray J Mazer 《Journal of ultrasound in medicine》2002,21(2):129-133
OBJECTIVE: To assess the accuracy of three-dimensional color Doppler sonography and uterine artery arteriography in depicting changes in fibroid vascularity before and after embolization. METHODS: Preembolization and postembolization three-dimensional color Doppler sonography and selective uterine artery arteriography were retrospectively compared in 15 patients who underwent uterine artery embolization for treatment of symptomatic fibroids. Three-dimensional color Doppler sonography was performed by using a scanner with color power angiographic imaging capability. Vascularity was quantified by using an estimation of power-weighted pixel density as described by our group in previously published studies. Uterine artery arteriography was performed by using a standard selective microcatheter embolization technique. For purposes of comparison, fibroids were classified as either hypervascular or hypovascular relative to myometrial vascularity before and minutes to several hours after uterine artery embolization. Changes in fibroid vascularity (i.e., from hypervascular to hypovascular) as depicted by three-dimensional color Doppler sonography were compared with those shown on uterine artery arteriography and classified as being in agreement or disagreement. RESULTS: In 13 (87%) of 15 patients there was agreement; in 2 (13%) of 15 there was disagreement. In both cases of disagreement, three-dimensional color Doppler sonography showed collateral flow not depicted by uterine artery arteriography The mean reduction in quantitated vascularity after uterine artery embolization was 44% (range, 19%-78%). CONCLUSIONS: Three-dimensional color Doppler sonography accurately depicts fibroid vascularity and in some cases can reveal collateral flow not depicted by uterine artery arteriography. 相似文献
95.
96.
Rectus sheath haematoma is a well‐documented but unusual cause of acute abdomen. Combination of clinical features and appropriate radiological investigations can make for a prompt diagnosis. Most authors advocate conservative management and it has been reported that patients were directly discharged from the emergency department. We report a case of rectus sheath haematoma which progressed with clinical deterioration and necessitated surgical intervention for clot evacuation. Causes, physical signs, radiological features and classification of rectus sheath haematoma are discussed. It may be necessary to continue close clinical monitoring after diagnosis of rectus sheath haematoma. 相似文献
97.
Seong‐II BIN Shing‐Sheng WU Xiaofeng ZENG Alan MOORE Nicole FRANK 《International journal of rheumatic diseases》2007,10(3):190-197
Aim: The aim of the current study was to assess the efficacy, safety, and tolerability of lumiracoxib 200 mg once daily (o.d.) in relieving osteoarthritis (OA) knee pain in patients in China, Taiwan, and South Korea. Methods: Patients of either sex (aged ≥ 18 years) with symptomatic, primary OA of the knee for ≥ 3 months were eligible for inclusion if they had OA pain intensity of ≥ 40 mm (100 mm visual analogue scale [VAS]) in the target knee joint during the previous 24 h. Patients were required to undergo regular non‐steroidal anti‐inflammatory drug therapy for ≥ 6 weeks. After 3–7 days of screening, patients were randomized (1 : 1) to receive either lumiracoxib 200 mg o.d. or celecoxib 200 mg o.d. The primary efficacy comparison between the study groups was overall OA pain intensity (VAS) in the target knee after 6 weeks of treatment. Results: The mean overall OA pain intensity (VAS) in the target knee after 6 weeks decreased from 60.6 mm to 35.7 mm and 60.5 mm to 36.1 mm in the lumiracoxib and celecoxib groups, respectively. Both study groups showed similar results in terms of improvement in both patient's and physician's global assessment of disease activity and functional health status. The percentage of adverse events (AEs) in the lumiracoxib and celecoxib groups (40.3% and 37.9%, respectively) was similar, as was the proportion of treatment‐related AEs (21.0% and 18.2%, respectively). Conclusions: Lumiracoxib 200 mg o.d. provided effective and well‐tolerated pain relief similar to that achieved with celecoxib 200 mg o.d. in knee OA patients. 相似文献
98.
Antonio Z Gimeno‐García Adolfo Parra‐Blanco David Nicols‐Prez Cipriano Manzano‐Sanz Rafael Mndez‐Medina Enrique Quintero 《Digestive endoscopy》2006,18(2):144-146
Gastric mucormycosis involvement is a rare condition that usually occurs in inmunocompromised patients and frequently has a fatal outcome. We report the case of a 73‐year‐old woman admitted to the intensive care unit with severe bleeding after an acute pulmonary disease. Upper endoscopy disclosed wide and deep necrotic ulcers in the body and fundus of the stomach and greenish exudates with the antrum and the duodenum undamaged. Autopsy revealed an invasive mucormycosis and a severe atheromatosis. Several predisposing factors for mucormycosis infection have been reported until now. We postulate that ischemic gastritis could be a predisposing factor for colonization of zygomycete. 相似文献
99.
Karissa Y. Kim PharmD CACP ; Kelly Epplen PharmD CACP ; Farzin Foruhari MD ; Hattie Alexandropoulos PharmD 《Progress in cardiovascular nursing》2006,21(2):1-4
A 79-year-old man with a history of deep vein thrombosis and pulmonary embolism received anticoagulation therapy with warfarin 5 mg daily for 8 months. He was diagnosed with osteomyelitis and underwent partial metatarsal resection of his right foot. After surgery, antibiotics were initiated including ertapenem sodium 1 g intravenously every 24 hours, vancomycin 1400 mg intravenously every 24 hours, and rifampin 300 mg by mouth twice daily. Achieving a therapeutic level of anticoagulation was difficult despite escalating doses of warfarin, because of the interaction with rifampin. A 5- to 6-fold increase in warfarin dose was prescribed to reach therapeutic international normalized ratios (INRs), but even these increases were insufficient to maintain his INR in the therapeutic range. After rifampin was discontinued, warfarin doses were gradually reduced over the next 2 months. When concurrent warfarin-rifampin therapy is necessary, vigilant monitoring is imperative and significant increases in warfarin doses are likely. 相似文献
100.